Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer
Shots:
- The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib- 600mg- bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with an epithelial ovarian- fallopian tube or primary peritoneal cancer
- The P-III ARIEL3 study results: IIT population & BRCA mutation- Mean QA-PFS in (12.02 vs 5.74 & 15.28 vs 5.92 mos.); Mean Q-TWiST (13.32 vs 6.44 & 16.42 vs 6.70 mos.); Q-TWiST (13.16 vs 6.40 & 16.24 vs 6.68 mos.) respectively
- Rubraca (rucaparib) is an oral PARP1- PARP2 and PARP3 inhibitor and has received FDA’s approval as a monothx. for the maintenance treatment of recurrent epithelial ovarian- fallopian tube- or primary peritoneal cancer in Apr’18
Ref: BusinessWire | Image: Linkedin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com